Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble ur...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Loosen, Sven H., Gorgulho, Joao, Jördens, Markus S., Schulze-Hagen, Maximilian, Beier, Fabian, Vucur, Mihael, Schneider, Anne T., Koppe, Christiane, Mertens, Alexander, Kather, Jakob N., Tacke, Frank, Keitel, Verena, Brümmendorf, Tim H., Roderburg, Christoph, Luedde, Tom
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047604/
https://ncbi.nlm.nih.gov/pubmed/33869041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646883
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi